Physician profile
Ivan Diaz
NPI 1972575389
$629.89
in general payments reported to CMS, 2019-2025
14 companies · $63.69 in 2025
The $63.69 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.91 · 2020: $15.66 · 2023: $243 · 2024: $214 · 2025: $63.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $146.57 | 2024 | Restrata Wound Matrix |
| Pfizer INC. | $131.71 | 2019-2025 | |
| Ethicon INC. | $109.37 | 2023 | Monarch Platform |
| Amarin Pharma, INC. | $53.68 | 2019 | |
| Novo Nordisk INC | $40.64 | 2023 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $22.36 | 2023 | |
| Lilly USA, LLC | $18.80 | 2023 | Mounjaro |
| Nestle Healthcare Nutrition INC. | $17.92 | 2023 | |
| Glaxosmithkline, LLC. | $16.13 | 2025 | Trelegy Ellipta, Arexvy |
| Aimmune Therapeutics, INC. | $16.09 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $15.66 | 2020 | |
| Boston Scientific Corporation | $14.59 | 2023 | Watchman Access System |
| Smith+Nephew, INC. | $14.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.